<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[《中国临床新医学》杂志编辑部 -->专家论坛·高尿酸血症与痛风]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research progress in the related mechanisms of uric acid and bone metabolism and osteoporosis]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20211103&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　With the aging of China′s population and the gradual changes in lifestyle and diet structure, the morbidity rates of osteoporosis, hyperuricemia and gout are on the rise and showing a trend of younger age, which has become an important public health problem in China. In recent years, the relationship between uric acid and bone metabolism has gradually attracted the attention of scholars. There have been many in-depth studies on the relationship between uric acid and bone metabolism and mechanisms. In the pathogenesis of osteoporosis, oxidative stress is involved in the modulation and control of osteoblasts and osteoclasts. Uric acid, as an effective antioxidant in the body, affects bone metabolism to a certain extent. Some studies have proposed that uric acid level affects bone metabolism and is correlated with osteoporosis. However, other studies have shown that the relationship between uric acid and osteoporosis is affected by various confounding factors and this relationship is uncertain.Therefore, there are still controversies in previous research conclusions. In this paper, the research progress in the related mechanisms of uric acid and bone metabolism and osteoporosis is reviewed.]]></description>
<pubDate>2021/12/3 11:58:03</pubDate>
<category><![CDATA[专家论坛·高尿酸血症与痛风]]></category>
<author><![CDATA[MO Jia-min, YAN Xiao-dong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MO Jia-min, YAN Xiao-dong</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20211103&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of imaging examinations in gouty arthritis]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20211104&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　The incidence rates of hyperuricemia and gouty arthritis are increasing year by year, and in China, the patients have an obvious younger trend. In recent years, imaging techniques including ultrasound, computed tomography(CT) and magnetic resonance imaging(MRI) have been increasingly applied to the diagnosis and identification of gouty arthritis. The popularization of these techniques not only improves the sensitivity and specificity of the diagnosis, but also effectively evaluates the severity of the disease and the extent of urate deposition, and monitors the effect of urate lowering therapy(ULT). For the past many years, in addition to measuring blood uric acid levels, joint X-ray examination has always been the main auxiliary method for diagnosis of gouty arthritis, but it is not conducive to the early diagnosis due to its poor sensitivity. In recent years, with the continuous dissemination and application of dual-energy CT, ultrasound and MRI techniques in clinical practice, the sensitivity and specificity of the diagnosis of gouty arthritis have been greatly improved. Simultaneously, the levels of early standardized diagnosis and treatment of gouty arthritis have been significantly improved.]]></description>
<pubDate>2021/12/3 11:58:03</pubDate>
<category><![CDATA[专家论坛·高尿酸血症与痛风]]></category>
<author><![CDATA[ZHANG Xue-wu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xue-wu</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20211104&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[A study on correlation between SLC2A9 gene polymorphism loci and primary gout in Guangxi Zhuang population]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20211105&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To explore the correlation between the solute carrier family 2, member 9(SLC2A9) gene single  nucleotide polymorphisms(SNPs)and primary gout in Guangxi Zhuang population. <b>Methods</b>　A total of 246 primary gout patients in Guangxi Zhuang population and 202 healthy controls were enrolled in this study. The clinical data and laboratory indexes such as serum uric acid(UA), fasting blood glucose, serum total triglyceride(TG), serum total cholesterol(TC), high density lipoprotein cholesterol(HDL-C), low density lipoprotein cholesterol(LDL-C), serum creatinine(Cr) and blood urea nitrogen(BUN) were collected. The differences in the clinical data and laboratory indexes were compared between the two groups. The genotypes of four loci of SLC2A9 gene(rs10489070, rs734553, rs3733591, rs16890979) were detected by Taqman-MGB probe. The genotypes and allele distribution frequencies were compared between the two groups. <b>Results</b>　The levels of body mass index(BMI), TG, TC, LDL-C, Cr and UA in the gout group were significantly higher than those in the control group(<i>P</i><0.05). Compared with the patients without tophi, the patients with tophi had older age, longer course of disease, more joints involved, higher incidence of nephrolithiasis, and higher levels of TG, TC, LDL-C, Cr and UA, and there were significant differences between the two groups(<i>P</i><0.05). The genotypes and frequencies of allele distributions in rs10489070 and rs3733591 were significantly different between the gout group and the control group(<i>P</i><0.05). The <i>OR</i> value of gout in the individuals carrying the C allele was 1.413(95%<i>CI</i>: 1.009-1.980) and 1.739(95%<i>CI</i>: 1.331-2.271) respectively. rs3733591(CC)(<i>aOR</i>=2.113, 95%<i>CI</i>: 1.536-3.951), rs10489070(CC)(<i>aOR</i>=1.981, 95%<i>CI</i>: 1.123-3.156) were the independent risk factors for gout. rs3733591(CC)(<i>aOR</i>=2.358, 95%<i>CI</i>: 1.114-3.221) and rs10489070(CC)(<i>aOR</i>=2.115, 95%<i>CI</i>: 1.689-4.547) were the independent risk factors for tophus. <b>Conclusion</b>　In the Zhuang population in China, rs10489070(CC) and rs3733591(CC) genotypes of SLC2A9 gene are the independent risk factors for gout and tophus. However, the specific mechanisms of the susceptible loci affecting the pathogenesis of gout are still unclear, and the function of related SNPs needs to be further studied.]]></description>
<pubDate>2021/12/3 11:58:03</pubDate>
<category><![CDATA[专家论坛·高尿酸血症与痛风]]></category>
<author><![CDATA[HUO Xiao-cong, HUANG Xin-xiang, ZHU Xia, et al.]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUO Xiao-cong, HUANG Xin-xiang, ZHU Xia, et al.</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20211105&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Diagnostic value of dual-energy CT in the clinical course of gout]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20211106&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To explore the diagnostic value of dual-energy computed tomography(CT), X-ray plain film and magnetic resonance imaging (MRI) in different clinical stages of gout. <b>Methods</b>　A total of 80 patients with hyperuricemia and gout who were the outpatients or inpatients in Hepu People′s Hospital from January 2020 to August 2021 were selected and divided into asymptomatic hyperuricemia group(7 cases), acute episode group(37 cases), intermittent episode group(12 cases), and chronic tophi lesion group(24 cases) according to the staging criteria of the clinical course of gout. The patients including fifty-six cases with gout at ankle joints, 21 cases at knee joints, 10 cases at hand joints, 17 cases at two sites and 8 cases at multiple sites were examined by dual-energy CT, X-ray plain film and MRI. The positive results of the three imaging examinations in the stages of the clinical course of gout were analyzed. <b>Results</b>　The total positive rates of dual-energy CT, X-ray plain film and MRI were 93.8%, 37.5% and 58.8%, respectively. The positive rate of dual-energy CT in asymptomatic hyperuricemia stage was 57.1%, but no positive signs were found in X-ray plain film and MRI. <b>Conclusion</b>　Dual-energy CT is helpful to find urate crystals in joints and the surrounding soft tissues of patients with gout, and the positive results showed by dual-energy CT are earlier than those showed by X-ray and MRI imaging. Dual-energy CT has higher clinical application value as a specific diagnosis method of gout.]]></description>
<pubDate>2021/12/3 11:58:03</pubDate>
<category><![CDATA[专家论坛·高尿酸血症与痛风]]></category>
<author><![CDATA[PANG Hua-qing, LONG Lin-jun, HUANG Hai-cheng, et al.]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>PANG Hua-qing, LONG Lin-jun, HUANG Hai-cheng, et al.</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20211106&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>